BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elekta Announces First Step in Integrating Treatment Planning With MOSAIQ Oncology Information System


1/7/2013 11:11:12 AM

ATLANTA, Jan. 7, 2013 /PRNewswire/ -- As part of a process to completely integrate the patient's electronic medical record (EMR) with treatment planning activities, Elekta has introduced MOSAIQ® Evaluate*, a toolset that unites plan and dose review capabilities in a single software framework, MOSAIQ Oncology Information System (OIS). Uniting MOSAIQ and powerful treatment planning review capabilities streamlines planning activities inside the patient chart, reducing patient wait times and delays and improving efficiency and productivity in the department. Elekta recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MOSAIQ Evaluate.

"The development of MOSAIQ Evaluate establishes a new standard of oncology treatment planning management in a single software environment. Our belief is that clinical decision-making is improved when the radiotherapy team can access and review treatment and patient data from one source, MOSAIQ," says Todd Powell, Executive Vice President, Elekta Software. "It's the first step in a process in which we will steadily integrate advanced toolsets inside MOSAIQ, ultimately creating an advanced, comprehensive treatment planning solution inside the EMR."

With MOSAIQ Evaluate, the entire radiation oncology team can access and review treatment plans and patient data from the patient's chart, streamlining the radiotherapy workflow. It enables plan review from virtually any treatment planning system and for any treatment modality, in addition to comparison of multiple plans.

To support the multidisciplinary team, MOSAIQ Evaluate offers specific benefits for the radiation oncologist, the physicist and the dosimetrist. Radiation oncologists and physicists will now be able to review plans at their MOSAIQ workstation and view a "to-do" list of plans needing review. MOSAIQ Evaluate also enables the physicist to identify approved plan information side-by-side with all treatment fields, approve treatment fields directly from the Plan Worklist, and view imported DRR's alongside the treatment plan. With MOSAIQ Evaluate, dosimetrists will be able to use the Plan Worklist to identify approved plans, triggering the next step in the workflow.

To learn more, visit www.elekta.com/evaluate.

*MOSAIQ Evaluate is not available for sale or distribution in all markets. Please contact the local Elekta representative for details.

For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

SOURCE Elekta



Read at BioSpace.com

Elekta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES